The July 2026 Medicare GLP-1 Expansion: What Men Over 65 Need to Know

If you're a man on Medicare who has been paying $500-1,300 per month out of pocket for Wegovy or Zepbound — or who has been unable to afford GLP-1 treatment at all — July 1, 2026 is the most important date in your healthcare calendar this decade.

The Medicare GLP-1 Bridge is a nationwide pilot program launching July 1 that will cover FDA-approved weight loss medications at a flat $50 per month copay. It's the first time Medicare has ever covered prescription drugs specifically for obesity — ending a statutory prohibition that has been in place since 2003.

What's Covered

The Bridge covers three FDA-approved weight loss medications:

• Wegovy (semaglutide) — both the injectable pen and the new oral tablet
• Zepbound (tirzepatide) — the KwikPen formulation
• Foundayo — the oral formulation

These are brand-name, FDA-approved medications only. The Bridge does not cover compounded semaglutide, compounded tirzepatide, Ozempic (which is approved for diabetes, not weight loss), or Mounjaro (diabetes indication).

Who Qualifies

To be eligible for the Medicare GLP-1 Bridge, you must meet all of the following:

1. Enrolled in a Medicare Part D plan. This is the prescription drug portion of Medicare. If you have Medicare but no Part D coverage, you won't qualify until you enroll.
2. BMI of 35 or higher at the time GLP-1 therapy was initiated, OR
3. BMI of 27 or higher with at least one weight-related condition — including heart disease, type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, or prediabetes
4. Prior authorization submitted by your prescribing provider attesting you meet the clinical criteria

Already on a GLP-1?

If you're already taking a GLP-1 for weight loss, you may still qualify — even if your BMI has dropped below the threshold since starting treatment. Your provider needs to attest that you met the BMI criteria at the time therapy was initiated. So if you started Wegovy at a BMI of 37 in 2024 and have since lost weight to a BMI of 32, the prior authorization should reference your starting BMI.

How It Works (Step by Step)

1. Talk to your doctor now (May-June). Don't wait until July 1. Discuss whether you meet the eligibility criteria and start the prior authorization paperwork in advance.
2. Your provider submits a prior authorization to a CMS-contracted central processor — not your Part D plan. This is a separate pathway from normal Part D claims.
3. Fill your prescription at any pharmacy. Pharmacies don't need to opt in. The pharmacy will collect your $50 copay and submit the claim to the central processor for reimbursement.
4. Continue monthly. The $50 copay stays flat regardless of which Part D benefit phase you're in — there's no deductible to meet first under this program.

What It Doesn't Cover (Read This Carefully)

• The $50 copay doesn't count toward your Part D deductible or the $2,100 annual out-of-pocket cap. It operates outside the standard Part D benefit.
• Low-income subsidy (LIS/Extra Help) doesn't apply. If you normally pay $5-10 copays through LIS, you'll still pay the full $50 under the Bridge program. For seniors on limited fixed incomes, $50/month may still be a barrier.
• No compounded medications. Only brand-name FDA-approved products are covered.
• The program ends December 31, 2027. Originally set to end in 2026, CMS extended it through 2027. What happens after that depends on whether the BALANCE Model launches in Medicare Part D in 2028 — which is uncertain.

Why This Matters More for Men

More than one-third of Medicare beneficiaries are classified as obese, and another 35% are overweight. For men specifically, the stakes are elevated:

• Cardiovascular disease is the leading cause of death in American men over 65. The SELECT trial showed semaglutide reduces major cardiac events by 20%.
• Sleep apnea affects men at 2-3x the rate of women, and Zepbound is the first drug ever FDA-approved for this condition.
• Testosterone decline accelerates with obesity and aging. ENDO 2025 data shows GLP-1 therapy can normalize testosterone in 77% of men — potentially reducing or eliminating the need for TRT.
• Mobility and independence — maintaining a healthy weight and preserving muscle mass directly affects quality of life, fall risk, and the ability to live independently as you age.

Action Steps: What to Do Right Now

This is a historic moment for Medicare beneficiaries who have been priced out of medications that could genuinely extend their healthy lifespan. The window is open. The cost is $50/month. The question is whether you walk through it.